Cargando…

Physiologically-based pharmacokinetic model for clozapine in Korean patients with schizophrenia

Clozapine has been used as a treatment of schizophrenia. Despite its large interindividual variability, few reports addressed the physiologically-based pharmacokinetic modeling and simulation (PBPK M&S) of clozapine in patients. This study aimed to develop a PBPK M&S of clozapine in Korean p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Joomi, Kim, Min-Gul, Jeong, Hyeon-Cheol, Shin, Kwang-Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Clinical Pharmacology and Therapeutics 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020364/ https://www.ncbi.nlm.nih.gov/pubmed/33854999 http://dx.doi.org/10.12793/tcp.2021.29.e3

Ejemplares similares

Prediction of the Drug–Drug Interaction Potential between Tegoprazan and Amoxicillin/Clarithromycin Using the Physiologically Based Pharmacokinetic and Pharmacodynamic Model
por: Wei, Zhuodu, et al.
Publicado: (2023)

Evaluation of the Effect of CYP2D6 Genotypes on Tramadol and O-Desmethyltramadol Pharmacokinetic Profiles in a Korean Population Using Physiologically-Based Pharmacokinetic Modeling
por: Jeong, Hyeon-Cheol, et al.
Publicado: (2019)

Predicting the systemic exposure and lung concentration of nafamostat using physiologically-based pharmacokinetic modeling
por: Jeong, Hyeon-Cheol, et al.
Publicado: (2022)

Integration of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Tegoprazan and Its Metabolite: Application for Predicting Food Effect and Intragastric pH Alterations
por: Jeong, Hyeon-Cheol, et al.
Publicado: (2022)

The Effect of Liver and Kidney Disease on the Pharmacokinetics of Clozapine and Sildenafil: A Physiologically Based Pharmacokinetic Modeling
por: Ghoneim, Amira M, et al.
Publicado: (2020)

Evaluation of sex differences in the pharmacokinetics of oral sumatriptan in healthy Korean subjects using population pharmacokinetic modeling
por: Ohk, Boram, et al.
Publicado: (2022)

Population pharmacokinetic analysis of tramadol and O-desmethyltramadol with genetic polymorphism of CYP2D6
por: Lee, Joomi, et al.
Publicado: (2019)

Urinary Metabolomic Profiling after Administration of Corydalis Tuber and Pharbitis Seed Extract in Healthy Korean Volunteers
por: Jeong, Hyeon-Cheol, et al.
Publicado: (2021)

Combination of Electroconvulsive Therapy and Clozapine in Treatment-Resistant Schizophrenia
por: Kim, Jung Hyun, et al.
Publicado: (2018)

Aripirazole augmentation in clozapine-associated obsessive-compulsive symptoms in schizophrenia
por: Eryılmaz, Gül, et al.
Publicado: (2013)

Population Pharmacokinetics of Clozapine and Norclozapine and Switchability Assessment between Brands in Uruguayan Patients with Schizophrenia
por: Olmos, Ismael, et al.
Publicado: (2019)

USE OF CLOZAPINE IN CHILDHOOD SCHIZOPHRENIA
por: Srinivasan, T.N., et al.
Publicado: (1997)

Combining Therapeutic Drug Monitoring and Pharmacokinetic Modelling Deconvolutes Physiological and Environmental Sources of Variability in Clozapine Exposure
por: Wills, Kenneth H., et al.
Publicado: (2021)

Effectiveness of Electroconvulsive Therapy Augmentation on Clozapine-Resistant Schizophrenia
por: Kim, Hye Sung, et al.
Publicado: (2017)

Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats
por: Song, Yoo-Kyung, et al.
Publicado: (2021)

Interaction of clozapine with metformin in a schizophrenia rat model
por: Horvath, G., et al.
Publicado: (2021)

Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans
por: Bae, Soo Hyeon, et al.
Publicado: (2018)

Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects
por: Kim, Yu Kyong, et al.
Publicado: (2018)

Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice
por: Jendryka, Martin, et al.
Publicado: (2019)

Bioequivalence of Generic and Brand Name Clozapine in Korean Schizophrenic Patients: A Randomized, Two-Period, Crossover Study
por: Woo, Young Sup, et al.
Publicado: (2015)

Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study
por: Park, Sung Min, et al.
Publicado: (2014)

S194. CLOZAPINE AND ELECTROCONVULSIVE THERAPY AUGMENTATION IN ADOLESCENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA
por: Jeong Park, Kee, et al.
Publicado: (2020)

Effectiveness of clozapine in treatment-resistant schizophrenia
por: Raguraman, Janakiraman, et al.
Publicado: (2005)

Clozapine: Improvement of Negative Symptoms of Schizophrenia
por: Khan, Afaque H, et al.
Publicado: (2017)

Clozapine Response in Schizophrenia and Hematological Changes
por: Blackman, Graham, et al.
Publicado: (2021)

Clozapine discontinuation withdrawal symptoms in schizophrenia
por: Blackman, Graham, et al.
Publicado: (2021)

Management of patients with Clozapine Resistant Schizophrenia
por: Rajendran*, Nithya Ragavi, et al.
Publicado: (2022)

A compatibility evaluation between the physiologically based pharmacokinetic (PBPK) model and the compartmental PK model using the lumping method with real cases
por: Ryu, Hyo-jeong, et al.
Publicado: (2022)

Prediction of Pharmacokinetics of IDP-73152 in Humans Using Physiologically-Based Pharmacokinetics
por: Lee, Myongjae, et al.
Publicado: (2022)

Clozapine prescribing barriers in the management of treatment-resistant schizophrenia: A systematic review
por: Baig, Anum Iqbal, et al.
Publicado: (2021)

Population Pharmacokinetics of Clozapine: A Systematic Review
por: Albitar, Orwa, et al.
Publicado: (2020)

Difference between treatment-resistant schizophrenia and clozapine-resistant schizophrenia
por: Tseng, Ping-Tao, et al.
Publicado: (2022)

Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study
por: Johannsen, Claas-Frederik, et al.
Publicado: (2022)

Clozapine Reverses Dysfunction of Glutamatergic Neurons Derived From Clozapine-Responsive Schizophrenia Patients
por: Hribkova, Hana, et al.
Publicado: (2022)

Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans
por: Jeong, Yoo-Seong, et al.
Publicado: (2021)

Long-Term Changes in Self-Report Auditory Verbal Hallucinations in Patients with Schizophrenia Using Clozapine
por: Chung, In Won, et al.
Publicado: (2019)

Machine Learning Algorithm-Based Prediction Model for the Augmented Use of Clozapine with Electroconvulsive Therapy in Patients with Schizophrenia
por: Oh, Hong Seok, et al.
Publicado: (2022)

Effect of green tea catechins on the pharmacokinetics of digoxin in humans
por: Kim, Tae-Eun, et al.
Publicado: (2018)

Dose-proportional pharmacokinetic properties of GLA5PR GLARS-NF1 controlled-release pregabalin in healthy Korean volunteers: a randomized, open, single-dose, parallel study
por: Shin, Kwang-Hee, et al.
Publicado: (2018)

A False Case of Clozapine-Resistant Schizophrenia
por: Maia-de-Oliveira, J. P., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ei8k2oeoqlt9ht830qvh8ldq3m